Abilify Attorney in Pennsylvania
Fight with a Pennsylvania Defective Drugs Lawyer
In 2002, Abilify (aripiprazole) was FDA-approved to treat schizophrenia. Two years later, it was approved
to treat bipolar disorder; in 2007 it was also approved to treat a major
depressive disorder. It is thought that Abilify has a strong effect on
important chemicals in the brain, such as dopamine, which controls pleasure.
Excessive levels of dopamine can influence compulsive, addictive behaviors.
Because Abilify acts as a sort of dopamine, there have been numerous reports
of patients developing addictive habits as a result of taking the medication.
Once the medication was stopped, the addiction stopped as well.
Has your life been negatively impacted by Abilify?
Contact Handler, Henning & Rosenberg LLP today. Since 1922, our firm has stood up for the rights of the injured. Let our
Pennsylvania defective drug attorney team fight on your behalf!
Side Effects of Abilify
Cases involving Abilify have shown that many individuals develop compulsive
habits ranging from gambling to overeating. In many cases, these individuals
experienced highly negative effects from these addictions. Throughout
the years, the FDA has released several warnings as to the side effects
of the drug.
FDA warnings have covered the following:
Diabetes & Hyperglycemia: In 2004, the FDA required that the drug manufacturers to add warnings
about increased diabetes and hyperglycemia risks to the labels.
Suicide Warning: In 2007, the FDA required that the label be updated with a Black Box
Warning indicating the increased dangers of suicide in patients under 24.
Death in the Elderly: In 2008, the FDA required Abilify’s labels to include a Black Box
Warning regarding an increased risk of death if used to treat dementia
in older patients.
Newborn Problems: In 2011, the FDA issued a warning informing pregnant women or women who
wanted to become pregnant that exposing an infant to Abilify in the third
trimester could cause abnormal muscle movement and withdrawal symptoms.
Impulse Control Problems: In 2016, the FDA issued a Safety Communication that warned individuals
about the control problems associated with Abilify.
Call Handler, Henning & Rosenberg LLP for a Free Case Evaluation
As one of the largest firms in the area, we can devote a tremendous amount
of time and resources to your case. Since the founding of our firm, our
team of legal professionals has won millions on behalf of our clients
and are dedicated to upholding a tradition of excellence and success.
We are one of the only firms capable of handling mass torts in the area,
and can efficiently represent your personal needs and concerns.
We are available 24/7 to take your calls.
Call (888) 498-3023 for a free case evaluation with one of our Pennsylvania